Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The study, which was funded by Lilly, included 751 people from across the U.S. who were overweight or had obesity and at least one other weight-related health problem, but not diabetes.

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said.

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Weight-loss Medications May Also Benefit Common Medical Problem, Study Finds The randomized, controlled trial — called SURMOUNT-5 — included 751 people throughout the U.S. and Puerto Rico who ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

"Forever" PFAS chemicals might hamper a teenager's ability to drop excess weight, even if they've undergone weight-loss ...

Key Takeaways Zepbound helped patients lose 50 pounds, compared to 33 pounds with Wegovy The study showed Zepbound users lost 20% of body weight Both drugs caused some mild stomach-related side ...